MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial DNA. It is part of a newer class of signaling molecules showing that mitochondria do more than make energy—they can also send metabolic signals throughout the body. MOTS-c has been studied for its relationship with AMPK, insulin sensitivity, skeletal muscle metabolism, and adaptation to metabolic stress. In foundational research, MOTS-c improved insulin sensitivity and metabolic homeostasis in mouse models Cell Metabolism study. Human studies have also measured circulating MOTS-c in relation to exercise and metabolic status human exercise study.

MOTS-c appears to act as a metabolic signaling peptide, with research linking it to AMPK activation, glucose utilization, skeletal-muscle metabolism, and cellular adaptation to energy stress. In animal studies, MOTS-c improved insulin sensitivity and reduced diet-related metabolic dysfunction research. Human work confirms that MOTS-c is present in circulation and interacts with exercise-related physiology, although the response is variable human research. MOTS-c is intended to support metabolic flexibility, energy utilization, and exercise recovery—not to act as a direct appetite suppressant or proven weight-loss drug.

MOTS-c has promising metabolic biology but a limited therapeutic human safety database, so Clinician screening and a defined protocol are necessary. Important considerations include glucose regulation, diabetes medications, pregnancy status, active serious illness, and other metabolic or peptide therapies. With subcutaneous treatment, local irritation, redness, bruising, or tenderness can occur. Because human interventional data are still early, unexpected systemic symptoms should be taken seriously rather than assumed to be part of an adaptation process. Patients should contact the clinical team for persistent dizziness, weakness, unusual glucose symptoms, allergic reactions, or any significant change in how they feel during treatment.

MOTS-c does not have a clinically established onset for injected metabolic-wellness use. Energy or exercise-tolerance changes, if they occur, may be noticed within the first 1–2 weeks, while metabolic and body-composition goals are better assessed over 4–8 weeks or longer. Progress should be tied to specific measures such as training tolerance, recovery, waist trends, or metabolic labs when appropriate.

Bowery Clinic peptides are higher-strength and clinically dosed compared to most research facilities that use much lower concentrations. They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products.

Yes. All pharmacies in our network are fully licensed in the states where they operate and comply with all state board of pharmacy regulations. Unlike many peptide clinics, we partner exclusively with FDA-registered U.S. pharmacies that undergo rigorous evaluation and compliance checks.

Every patient receives treatment plans developed and monitored by licensed providers. This includes safe titration of dosages and ongoing medical oversight tailored to individual needs.

Injections deliver the medication directly into your system. This makes the absorption more consistent and effective. Troches are small dissolvable lozenges that sit in your mouth until they melt, slowly releasing medication through the lining of your cheek or under your tongue.